Core Viewpoint - Company Kemei Diagnostics has shown a significant increase in shareholder numbers and continues to innovate in the medical diagnostics field, despite a decline in revenue and net profit in the latest quarterly report [1]. Group 1: Company Performance - As of August 7, Kemei Diagnostics closed at 8.62 yuan, up 1.65%, with a rolling PE ratio of 33.50 times and a total market capitalization of 3.458 billion yuan [1]. - The latest quarterly report for Q1 2025 shows the company achieved operating revenue of 81.30 million yuan, a year-on-year decrease of 27.01%, and a net profit of 14.54 million yuan, down 62.12%, with a gross profit margin of 66.88% [1]. Group 2: Industry Comparison - The average PE ratio for the medical device industry is 54.79 times, with a median of 37.86 times, placing Kemei Diagnostics at the 68th position within the industry [1]. - The company’s static PE ratio is 27.21 times, and its price-to-book ratio is 2.42 times [2]. Group 3: Shareholder Information - As of March 31, 2025, Kemei Diagnostics had 11,024 shareholders, an increase of 1,412 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1]. Group 4: Innovation and Patents - During the reporting period, Kemei Diagnostics obtained 64 new domestic and international patents, including 33 domestic invention patents, 20 utility model patents, and 11 design patents, indicating strong innovation capabilities and technical reserves [1].

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Kemei Diagnostics, indicating a significant drop in its stock price and earnings compared to industry averages [1][2] - Kemei Diagnostics closed at 8.76 yuan, with a PE ratio of 34.04, marking a new low in 367 days, and a total market capitalization of 3.514 billion yuan [1] - The average PE ratio for the medical device industry is 54.32, with a median of 38.11, placing Kemei Diagnostics at the 68th position in the industry ranking [1][2] Group 2 - As of March 31, 2025, Kemei Diagnostics had 11,024 shareholders, an increase of 1,412 from the previous count, with an average holding value of 352,800 yuan and an average of 27,600 shares per shareholder [1] - The company specializes in the research, development, production, and sales of clinical immunochemistry luminescent diagnostic reagents and instruments, with key products including the LiCA and CC series [1] - In the latest quarterly report for Q1 2025, Kemei Diagnostics reported revenue of 81.3 million yuan, a year-on-year decrease of 27.01%, and a net profit of 14.5 million yuan, down 62.12%, with a gross margin of 66.88% [1]

Core Viewpoint - The company, Kemei Diagnostics, has shown a decline in revenue and net profit in the latest quarterly report, while its stock price has reached a new low in terms of rolling P/E ratio compared to the industry average [1][2]. Company Summary - Kemei Diagnostics closed at 7.73 yuan, up 2.11%, with a rolling P/E ratio of 30.04, marking a 77-day low and a total market capitalization of 3.101 billion yuan [1]. - The company operates in the clinical immunochemistry and chemiluminescence diagnostic testing sector, focusing on the research, production, and sales of diagnostic reagents and instruments [1]. - The main products include the LiCA series and CC series [1]. - In the reporting period, Kemei Diagnostics obtained 64 new domestic and international patents, including 33 domestic invention patents, 20 utility model patents, and 11 design patents, indicating strong innovation capability and technical reserves [1]. Financial Performance - For Q1 2025, Kemei Diagnostics reported revenue of 81.30 million yuan, a year-on-year decrease of 27.01%, and a net profit of 14.54 million yuan, down 62.12%, with a gross profit margin of 66.88% [1]. Industry Summary - The average P/E ratio for the medical device industry is 52.34, with a median of 36.99, placing Kemei Diagnostics at the 64th position within the industry [2]. - The average P/B ratio for the industry is 4.60, while Kemei Diagnostics has a P/B ratio of 2.17 [2]. - As of March 31, 2025, Kemei Diagnostics had 11,024 shareholders, an increase of 1,412 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1].